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It was six men of Indostan
To learning much inclined,
Who went to see the Elephant
(Though all of them were blind);
That each by observation
Might satisfy his mind.
John Godfrey Saxe
The Blind Men and the Elephant (I)
Major strides have been made during the last decade in the
management of patients with congestive heart failure. We
now have a variety of new inotropic and vasodilator drugs
that can produce short- and long-term hemodynamic and
clinical improvement in these patients with an acceptable
frequency of adverse reactions (2). The changes produced
by these new approaches, however, have generally been
less dramatic than those that occurred when potent diuretics
were first introduced in the management of this disorder.
Although many patients experience marked relief of their
disabling symptoms after institution of treatment with vaso-
dilator and inotropic agents, the improvement in others is
subtle and may only become apparent during prolonged
therapy or when effective treatment is withdrawn. Such
beneficial changes, although quite important, may be dif-
ficult to discern in a clinical setting where symptoms may
be greatly influenced by variable compliance with diet and
medications and by an unpredictable progression of the un-
derlying disease.
How then are we to judge the efficacy of drug therapy
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in the patient with congestive heart failure? The problem
not only is germane to the clinician who is caring for the
individual patient, but is critical to the clinical investigator,
who must develop rational end points that can be used in
the design of studies to evaluate the utility of new therapeutic
agents. Such trials form the basis of the approval of these
drugs by governmental regulatory agencies charged with the
responsibility for releasing only safe and effective drugs to
the general public.
At first glance, it might appear that a number of ap-
proaches can be used to evaluate the status of patients with
congestive heart failure. We may inquire about symptoms;
we may assess clinically the degree of fluid retention; we
may evaluate left ventricular function noninvasively by
echocardiography or radionuclide ventriculography; we may
perform invasive hemodynamic testing to measure cardiac
output and ventricular filling pressures; we may measure
functional capacity by treadmill or bicycle exercise testing;
and we may attempt to evaluate the impact of treatment on
the natural history of the disease. Which of these six ap-
proaches best reflects the efficacy of drug therapy? Or, like
the six blind men describing different parts of the elephant,
does each approach provide only a limited perspective of a
highly complex pathophysiologic state that we cannot com-
pletely comprehend at the present time? The report by Leier
and his colleagues (3) in this issue of the Journal helps to
provide some insights into this important dilemma.
The First Blind Man: Symptoms as a
Therapeutic End Point
Because congestive heart failure is a clinical syndrome,
the most direct approach to its evaluation is to inquire about
symptoms of dyspnea and fatigue at rest and on exertion
and to estimate the degree of disability during the course
of daily physical activity. These symptoms are then com-
monly classified according to a categorical scale, such as
that of the New York Heart Association (4), and the efficacy
of a therapeutic intervention is judged using each patient as
his own historical control. Although simple, such a clas-
sification is not quantifiable, is subject to considerable in-
terobserver variability and lacks adequate sensitivity to de-
tect small but important changes in functional capacity.
Furthermore, many patients seeing a physician or receiving
a drug for the first time improve (in part) because they have
entered a new therapeutic environment, which (by increas-
ing the expectation of anticipated benefit) reduces anxiety
concerning symptoms and reinforces compliance with rec-
ommendations concerning treatment that may have been
previously made but ignored. The creation of such a ther-
apeutic environment occurs commonly in clinical practice,
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trial, in which the personal attention provided to the patient
reaches extreme levels. Such attention may explain why 20
to 30% of patients who enter heart failure trials show sig-
nificant improvement with placebo therapy (5-7), as was
the case in the study by Leier et al. (3). Consequently, the
frequency of clinical improvement after a specific drug in-
tervention is hard to evaluate (with confidence) in the ab-
sence of a placebo-treated group. Even when such a control
group is available for purposes of comparison, the evalu-
ation of symptoms remains a highly subjective matter that
is greatly influenced by the underlying biases of both the
patient and physician.
The Second Blind Man: Clinical Assessment
of Fluid Retention
Because the syndrome of congestive heart failure is a
sodium-avid state, it would seem logical to evaluate the
efficacy of drug therapy by observingthe patientfor changes
in signs of fluid retention, as can be assessed by physical
examination, body weight and the detection of pulmonary
congestion by chest radiography . Although changes in these
clinical variables provide an important means of measuring
the valueof diureticagents, they are not useful in measuring
. therapeutic benefits in patients treated with vasodilatorand
inotropicagents, whichmay producesymptomatic improve-
ment without notable changes in sodium balance (8). Fur-
thermore, most patients with heart failure undergo a ther-
apeutic diuresis as partof an attempt to optimize conventional
therapy before entry into a formal clinical trial; hence. pul-
monaryrales and peripheral edema are generallynot present
at the onset of therapy, even though patients may still have
severe symptoms. Finally, the evaluation of fluid retention
by physical and radiologicexamination remainshighly sub-
jective and is not easily quantified . Any drug effect as as-
sessed by these clinical variables may be particularly dif-
ficult to discern if the doses of concomitantly administered
diuretics are altered in an effort to maintain body weight,
as they were in the trial of Leier et al. (3).
The Third Blind Man: Noninvasive Measures
of Left Ventricular Function
Because most patients with congestive heart failure have
evidenceof severelydepressed left ventricularsystolicfunc-
tion, it would seem logical to evaluate the efficacy of drug
therapyby lookingat changes in left ventricularperformance
during the course of treatment. This assessmentcan be per-
formed by a variety of noninvasive techniques including
echocardiography, radionuclide ventriculography and sys-
tolic time intervals. All three techniquesare objective,quan-
tifiable and reproducible; the first two techniques have par-
ticular appeal, because they provide a direct visual image
of systolic ejection. Most importantly, these noninvasive'
measures have been shown to improve significantly during
effective treatment in controlled trials (5,9,10) and remain
unaltered during placebo therapy (10), as was the case in
the present trial by Leier et al. (3).
Unfortunately, vasodilator and inotropic drugs mayproduce
marked hemodynamic and clinical improvement in patients
with congestive heart failure without a notable change in
noninvasive indexes of left ventricular performance. Most
of the changes seen in these noninvasive measures during
effective treatment are quite small and fall within the range
of error for manyof these measurements (5, II); the benefits
induced by therapy must be large in magnitude to elicit
detectable changes in left ventricular function (12). Fur-
thermore, conventional imaging techniques only reflect
changes in ventricular volumes and in ventricular systolic
ejection; they do not quantify alterations in mitral or aortic
regurgitant flow or in ventriculardiastolic function, both of
which may corttribute significantly to the hemodynamic im-
provement seen during effective treatment (13,14). Con-
sequently, changes in noninvasive measuresof left ventric-
ular performance seen during the course of beneficial drug
therapy have not been shown to correlate closely with ob-
served changes in hemodynamic variables, clinical status
or functional capacity(12,15,16). In fact, the left ventricular
ejection fraction may increase significantly in patients with
heart failure whose clinical state has deteriorated during
.treatment and who have fared worse than their placebo-
treated counterparts (17).
The Fourth Blind Man: Invasive
Hemodynamic Evaluation
Becausemost patientswith severe heart failure have low
values for cardiacoutput and elevated values for ventricular
filling pressures at rest or during exercise, it would seem
logical to evaluate the efficacy of therapeutic interventions
based on their ability to correct the hemodynamic abnor-
malities seen in patients with this disorder. The measure-
ment of conventional cardiocirculatory variables also per-
mits the calculation of derived variables (for example, sys-
temic vascularresistance), which mayreflect the occurrence
of specific pharmacologic events. Such hemodynamic eval-
uations require the performance of right heart catheteriza-
tion, however, which carries its own risks and does not lend
itself to repeated observations over prolonged periods of
time. Nevertheless, when such serial measurements have
been made in controlled trials, they have provided com-
pelling evidence for drug efficacy, especially when similar
benefits were not seen in a parallel group treated with pla-
cebo (10,18,19).
Pitfalls of hemodynamic measurements. Unfortu-
nately, in the absence of a placebo-treated parallel group,
clinicians and investigators cannot be certain that the hemo-
dynamic changes seen after the administration of a new
therapeutic agent represent a true drug effect. Spontaneous
fluctuations in hemodynamic variables of small magnitude





are frequently seen in the absence of drug therapy and can
be interpreted as reaching statistical (and biologic) signifi-
cance. if postdrug effects are not assessed at fixed times
and if threshold values (that exceed the level of spontaneous
variability) are not used to rule out time-related rather than
drug-related events (20). If the investigator defines a " peak
effect" independently for each hemodynamic variable re-
gardless of the timeof occurrence. he creates a self-fulfi lling
prophecy that a true drug effect has indeed occurred. Even
if uniform times and threshold values are used. hemody-
namic changes mimicking a beneficial drug response may
be seen in the absence of effective drug therapy. if mea-
surements are performed immediately after right heart cath-
eterization or after the ingestion of a normal meal (21,22).
In particular, intravascular instrumentation appears to elicit
notable systemic vasoconstriction (presumably related to
overt or inapparent anxiety), which dissipates in 12 to 24
hours. If predrug measurements arc performed during this
immediate postcatheterization period. any subsequent mea-
surements performed days, weeks or months later can be
interpreted as showing beneficial effects, if such long-term
measurements are compared with the initial artifactually
vasoconstricted state; similar degrees of systemic vasocon-
striction may not be provoked during a second invasive study
(23). If such precautions are not taken, investigators may
report the occurrence of sustained hemodynamic improve-
ment in patients receiving ineffective treatment. Such pre-
cautions were taken in the study by Leier et at. (3). however.
and thus. no sustained hemodynamic effects were noted in
the placebo-treated group.
Initial versus long-term drug effects. The hemody-
namic effects of first doses of the study drug were not
reported by Leier et al. (3), although these were measured.
Why not? There appears to be a very complex relation
between the short- and the long-term effects of drugs used
in the treatment of congestive heart failure (24-26) . The
immediate benefits seen with some agents may not be sus-
tained during long-term treatment. because the pharmaco-
logic actions of the drug become attenuated with time or
because counteractive vasoconstrictor forces are activated
by therapy. Conversely, some patients who fail to show any
hemodynamic response to the initial administration of a new
therapeutic agent may have gradual improvement with time.
because prolonged exposure to the drug sets in motion changes
that progressively enhance the responsiveness of the cir-
culation to treatment (26) . Consequently. because the long-
term effects of therapy bear a variable and unpredictable
relation to the initial response to treatment. the potential
long-term efficacy of any therapeutic intervention cannot be
assessed by testing the hemodynamic response to the first
dose of a new drug (27).
Increased cardiac output as a marker of drug efficacy.
Should any change toward normal hemodynamic values be
considered a beneficial response in patients with congestive
heart failure? Because a reduction in forward flow would
appear to be one of the principal factors limitingthe exercise
tolerance of patients with severe heart failure (28), we might
be more encouraged by a drug that produces increases in
cardiac output and decreases in systemic vascular resistance
than by a drug that only reduces ventricular filling pressures
during long-term treatment. Previous studies (17) have shown,
however. that increases in cardiac output and decreases in
systemic vascular resistance at rest or during exercise do
not parallel changes in clinical status. Hence. drugs that
primarily affect the circulation in this fashion do not produce
consistent clinical benefits in patients with severe chronic
heart failure (6,17,29); conversely, drugs may improve
functional capacity without producing an increase in cardiac
output or a decrease in systemic vascular resistance at rest
or during exercise (10). These concepts are underscored by
the study of Leier et al. (3). whose patients showed little
clinical benefit from the study drug, although most of them
showed a sustained reduction in systemic vascular resistance
at rest and during submaximal exercise during long-term
treatment.
Decreased left ventricular filling pressure as a marker
of drug efficacy. Should we then be more encouraged by
a drug that produces a sustained decrease in ventricular
filling pressures rather than a long-term increase in cardiac
output? Because nearly all of the more newly developed
therapeutic agents for the treatment of heart failure work
(in part) by their ability to alter loading conditions in the
failing left ventricle. they must all produce important changes
in left ventricular end-diastolic volume. a common factor
in the calculation of both preload and afterload. Insofar as
changes in left ventricular filling pressure reflect changes in
left ventricular volume, we might expect a reduction in these
intracardiac pressures to provide a useful index of thera-
peutic effi cacy. In our experience, those patients with severe
chronic heart failure who have shown clinical improvement
have generally also shown significant decreases in left ven-
tricular filling pressure (2:5 mm Hg) during long-term drug
therapy (26,30,3 1). Such sustained decreases in left ven-
tricular fill ing pressure at rest and during exercise seem to
be sufficient in the absence of any change in cardiac output
or in systemic vascular resistance to produce notable clinical
benefits (10). In fact. the only three drugs that have been
shown to produce consistent symptomatic improvement in
patients with chronic heart failure in placebo-controlled trials
(isosorbide dinitrate, captopril and enalapril [2,10,18.19])
all produce markeddecreases in left ventricular filling pres-
sures at rest and during exercise during long-term treatment.
Therefore. it is not surprising that in the study by Leier et
al. (3), ineffective therapy with indoramin failed to produce
notable long-term decreases in left ventricular filling pres-
sure in the majority of treated patients.
Can we then reasonably suggest that (in the absence of
a placebo-treated group) a criterion of a 5 mm Hg or greater
decrease in left ventricular filling pressure during long-term





with congestive heart failure, assuming that the appropriate
methodologic precautions have been taken? Although the
observation of such a hemodynamic change is encouraging
and suggests the probability of an accompanying beneficial
clinical response, this criterion is not uniformly paralleled
by an improvement in symptoms in all patients or during
treatment with all drugs (32). This suggests that other factors
(such as physical conditioning, neurohormonal effects and
drug toxicity) are also important in mediating changes in
the clinical status of these severely ill patients.
The Fifth Blind Man: Objective Evaluation
of Functional Capacity
Because patients with severe heart failure have a notable
limitation of their functional capacity, it would seem logical
to evaluate tllj:: efficacy of therapeutic interventions based
on their ability to prolong the duration of tolerable exercise.
This assessment can be performed by a variety of nonin-
vasive techniques, the most common of which is the mea-
surement of total exercise duration using a graded treadmill
or bicycle exercise protocol. This approach is objective and
quantifiable. Most importantly, exercise duration has been
shown to improve significantly during effective treatment
with vasodilator drugs in controlled clinical trials (5,8,
10,18,19,29).
Unfortunately, the duration of exercise in congestive heart
failure is highly dependent on the motivation of both the
patient and the physician. During routine clinical conditions,
repeated testing predictably results in an improvement in
exercise performance, in part due to the increased familiarity
of the patient with the testing procedure and in part due to
an increased willingness of the physician to encourage the
patient to exercise to exhaustion. Such inadvertently sub-
maximal efforts can in part be detected by the failure of the
patient to achieve a respiratory gas exchange ratio greater
than 1.0, indicating that lactate accumulation has not oc-
curred and that exercise has ceased because of factors un-
related to circulatory function. If respiratory gas exchange
is not measured, therefore, a notable improvement in ex-
ercise duration may follow the institution of placebo therapy
and may be large enough to mimic a therapeutic drug re-
sponse in the absence of effective treatment (6,7,33).
Maximal oxygen uptake as a marker of drug efficacy.
The accurate measurement of respiratory gas exchange per-
mits oxygen consumption to be measured directly and, thus,
allows for the quantification of maximal exercise capacity
by the determination of maximal oxygen uptake (Vo-max).
This variable (Vo-max) has been proposed as a sensitive
index for assessing the efficacy of drug therapy in patients
with congestive heart failure (34). The accuracy of this
measurement, however, requires that a true maximal effort
has been extended by the patient; such a conclusion can be
reached only if a plateau in oxygen uptake can be demon-
strated despite further increments in exercise work load.
Although such a plateau can be demonstrated in normal
individuals, patients with congestive heart failure cannot
achieve a plateau in oxygen uptake during graded exercise
because they are limited by symptoms of dyspnea and fa-
tigue (35,36). Even if one redefines Vo-rnax as a failure of
oxygen uptake to increase by more than I mllkg per min
with incremental work loads (34), patients tend to stop ex-
ercising at a new work load before the next measurement
in oxygen uptake can be obtained; hence, it may be very
difficult to show that steady state conditions with reference
to oxygen uptake have been achieved (35). For this reason,
the observed peak V02 has been used by many investigators
to quantify exercise capacity, but in patients with a markedly
impaired exercise capacity, this measurement (which may
be significantly influenced by patient motivation) may differ
from the true V02max by up to 25%; therefore, increases
in peak V02 up to 25% can occur with repeated exercise
testing in such patients in the absence of effective therapy
(35). This may explain the significant increase in peak V02
seen in the patients treated with placebo in the study by
Leier et al. (3).
Anaerobic threshold as a marker of drug efficacy.
Because of the relative insensitivity of peak V02 as an index
of functional capacity in patients with congestive heart fail-
ure, several investigators have proposed the determination
of anaerobic threshold (as determined by either the blood
lactate or the ventilatory response to incremental exercise)
for the assessment of the functional state in this disorder
(34). Unfortunately, the point at which ventilation and car-
bon dioxide output increase disproportionate to oxygen up-
take may be extremely difficult to define (36); similarly,
blood lactate increases throughout exercise in patients with
severe heart failure without a clearly identifiable threshold
point. Both the lactate and ventilatory variables may change
so gradually that it is left to the discretion of the physician
to decide precisely when the anaerobic threshold has been
achieved (37). The problem is made infinitely more com-
plicated in the patient with a severely impaired peak V02 ,
in whom the initial work load of most exercise tests involves
levels of oxygen consumption very close to or above the
anaerobic threshold (36).
Submaximal exercise tests. The most serious limitation
of all of these tests of functional capacity is that they are
designed to evaluate exercise performance at maximal wor];
loads, but daily activities do not generally require an energy
expenditure in the maximal range. Hence, although drug
therapy may be considered to be highly effective when ac-
companied by a dramatic improvement in maximal exercise
performance, it is possible that clinical symptoms may be
significantly ameliorated by drug treatment that does not
increase maximal oxygen uptake but enhances exercise ca-
pacity at submaximal work loads that more realistically re-






or endurance tests have been developed and applied to the
evaluation of patients with congestive heart failure (35,38),
but there is as yet little experience with these tests to de-
termine their reproducibility, utility and validity.
The Sixth Blind Man: Survival as a
Therapeutic End Point
Even if drug therapy decreases the symptoms of patients
with congestive heart failure, the mortality of these patients
remains extremely high and is directly related to the severity
of the underlying disease. It would therefore seem logical
to evaluate the efficacy of a new therapeutic intervention
based on its ability to prolong survival. This end point is
the most laudable goal in the treatment of the patient with
congestive heart failure; it is also objective, quantifiable and
not readily subject to observer bias. Precisely such an ap-
proach has recently been used to demonstrate the utility of
the direct-acting vasodilator drugs, hydralazine and isosor-
bide dinitrate (39), in the management of congestive heart
failure. This drug combination had previously not been shown
to decrease symptoms or reduce signs of fluid retention or
result in improved noninvasive measures of left ventricular
performance or maximal exercise capacity in this disorder.
Unfortunately, until surrogate end points for survival can
be developed, the evaluation of the impact of any therapeutic
intervention on mortality can be assessed only by the per-
formance of a randomized, placebo-controlled trial in sev-
eral thousand patients. Such trials are complex and expen-
sive, however, and often provide little data concerning
pathophysiologic mechanisms. Nevertheless, they are nec-
essary to address the issue of survival, because the individual
clinician cannot evaluate the impact of treatment on mor-
tality in the individual patient. Yet, the clinical data derived
from such trials may be difficult to translate into practice,
because any therapeutic intervention that prolongs life but
fails to simultaneously lessen symptoms would remain an
unsatisfactory approach to the total management of the se-
verely limited patient with chronic heart failure.
Conclusions: The Synthesis of the Elephant
Which of the six approaches outlined provides the best
reflection of drug efficacy in the patient with severe chronic
heart failure? Each approach offers an important goal for
drug therapy, because each time the physician administers
a new drug for the treatment of heart failure, he tries to
reduce symptoms, to ameliorate fluid retention, to improve
invasive and noninvasive measures of left ventricular per-
formance, to enhance functional capacity and to prolong
life. Each time the clinical investigator evaluates a new drug
for the treatment of heart failure, he attempts to demonstrate
its value with respect to as many of these therapeutic end
points as is possible, preferably in the context of a placebo-
controlled trial. Unfortunately, each approach carries with
it important conceptual and methodologic limitations and,
thus, provides only an incomplete picture of a highly com-
plex and multifaceted pathophysiologic state. Therefore, if
we attempt (in our present state of knowledge) to consider
the information derived from each of these viewpoints as a
whole, the composite perspective is frequently confusing
and may be frankly contradictory.
Such confusion will be clarified in the future only by
efforts directed toward determining the relation among these
six therapeutic end points. What hemodynamic events are
responsible for the symptoms and exercise intolerance of
these patients? Do changes in left ventricular performance
or in exercise capacity translate into alterations in survival?
Can other therapeutic end points (that is, neurohormonal
events) provide an important mechanistic link among these
six approaches? Even partial answers to these questions will
offer important pathophysiologic insights into understanding
the syndrome of congestive heart failure during the next
decade.
In the land of the blind, the
one-eyed man is king.
Scottish proverb
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